Brief: Arix Bioscience Says Atox Bio's Drug Reltecimod Shows Positive Effect On Resolution Of Organ Dysfunction In Phase 3 Accute Trial
10/07/2020 13:06
July 10 (Reuters) - Arix Bioscience PLC ARIX.L :
* ARIX BIOSCIENCE PLC - ATOX BIO'S DRUG RELTECIMOD SHOWS
POSITIVE
EFFECT ON RESOLUTION OF ORGAN DYSFUNCTION IN PHASE 3 ACCUTE
TRIAL
* ARIX BIOSCIENCE PLC - NDA SUBMISSION PLANNED FOR Q3 2020
UNDER
ACCELERATED APPROVAL PATHWAY
Source text for Eikon: ID:nPRrA7748a
Further company coverage: ARIX.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arix Bioscience
See all newsBrief: Arix Bioscience Says Sale Of Harpoon Is Expected To Deliver Net Proceeds Of About $18.9 Mln
Brief: Arix Bioscience Total NAV Of £228.5 MLN As At 31 October 2023
Brief: RTW Biotech To Acquire Arix Bioscience's Assets
RTW Biotech to acquire Arix Bioscience's assets
Brief: Arix Bioscience Says Board Exploring Range Of Strategic Options For Co